ALK-1/ACVRL1, His, Cynomolgus
ALK-1/ACVRL1, His, Cynomolgus

Immobilized Human GDF-2, No Tag at 0.5 μg /ml (100 μl/well) on the plate. Dose response curve for ALK-1/ACVRL1, His, Cynomolgus, His Tag with the EC50 of 6.1ng/ml determined by ELISA.

ALK-1/ACVRL1, His, Cynomolgus

The purity of ALK-1/ACVRL1, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

ALK-1/ACVRL1, His, Cynomolgus

ALK-1/ACVRL1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

ALK-1/ACVRL1, His, Cynomolgus

Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Z04728
¥72,752.00

Ask us a question
Product Introduction
Species Cynomolgus
Protein Construction
ALK-1/ACVRL1 (Asp22-Gln118)
Accession # XP_005570958.1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System HEK293
Theoretical Molecular Weight 11.86 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 25-35 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles.

Examples
  • ALK-1/ACVRL1, His, Cynomolgus
    • ALK-1/ACVRL1, His, Cynomolgus

    Immobilized Human GDF-2, No Tag at 0.5 μg /ml (100 μl/well) on the plate. Dose response curve for ALK-1/ACVRL1, His, Cynomolgus, His Tag with the EC50 of 6.1ng/ml determined by ELISA.

  • ALK-1/ACVRL1, His, Cynomolgus
    • ALK-1/ACVRL1, His, Cynomolgus

    The purity of ALK-1/ACVRL1, His, Cynomolgus is greater than 95% as determined by SEC-HPLC.

  • ALK-1/ACVRL1, His, Cynomolgus
    • ALK-1/ACVRL1, His, Cynomolgus

    ALK-1/ACVRL1, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background Activin receptor-like kinase 1 (ALK1)-mediated endothelial cell signalling in response to bone morphogenetic protein 9 (BMP9) and BMP10 is of significant importance in cardiovascular disease and cancer. Structural analyses reveal a tripartite recognition mechanism that defines BMP9 and BMP10 specificity for ALK1, and predict that crossveinless 2 is not an inhibitor of BMP9, which is confirmed by experimental evidence.
Synonyms ACVRLK1; ORW2; ALK1; ALK-1; EC 2.7.11; HHT; HHT2; SKR3; TSR-I; ACVRL1

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.